Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.
cell free circulating tumor DNA (ctDNA)
circulating tumor cells (CTCs)
mFAST-SeqS
metastatic breast cancer (MBC)
prognosis
treatment response
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Aug 2019
14 Aug 2019
Historique:
received:
04
07
2019
revised:
31
07
2019
accepted:
12
08
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
17
8
2019
Statut:
epublish
Résumé
The aim of this study was to assess the prognostic and predictive value of an untargeted assessment of tumor fractions in the plasma of metastatic breast cancer patients and to compare circulating tumor DNA (ctDNA) with circulating tumor cells (CTC) and conventional tumor markers. In metastatic breast cancer patients (
Identifiants
pubmed: 31416207
pii: cancers11081171
doi: 10.3390/cancers11081171
pmc: PMC6721524
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Oesterreichische Nationalbank
ID : 16917
Organisme : Oesterreichische Nationalbank
ID : 14246
Organisme : Oesterreichische Nationalbank
ID : 15358
Organisme : krebshilfe steiermark
ID : NA
Organisme : Austrian Science Fund
ID : P28949-B28
Organisme : Christian Doppler Forschungsgesellschaft
ID : Fund for Liquid Biopsies for Early Detection of Cancer
Références
Anticancer Res. 1999 Jul-Aug;19(4C):3511-5
pubmed: 10629644
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Cancer. 2005 Oct 15;104(8):1742-50
pubmed: 16149088
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24
pubmed: 16857794
J Chromatogr A. 2007 Aug 31;1162(2):154-61
pubmed: 17561026
Anticancer Res. 2007 Jul-Aug;27(4A):1963-8
pubmed: 17649806
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Ann Oncol. 2010 Apr;21(4):729-33
pubmed: 19850639
Breast Cancer Res Treat. 2010 Jul;122(1):219-20
pubmed: 20130980
Clin Cancer Res. 2010 Oct 15;16(20):5011-8
pubmed: 20876796
Ann Oncol. 2012 Mar;23(3):618-24
pubmed: 21642515
Clin Chem. 2013 Jan;59(1):211-24
pubmed: 23065472
Sci Transl Med. 2012 Nov 28;4(162):162ra154
pubmed: 23197571
Int J Cancer. 2013 Jul 15;133(2):346-56
pubmed: 23319339
Clin Cancer Res. 2013 Mar 15;19(6):1596-602
pubmed: 23340302
N Engl J Med. 2013 Mar 28;368(13):1199-209
pubmed: 23484797
Genome Med. 2013 Apr 05;5(4):30
pubmed: 23561577
Nature. 2013 May 2;497(7447):108-12
pubmed: 23563269
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
PLoS Genet. 2014 Mar 27;10(3):e1004271
pubmed: 24676216
Nat Med. 2014 Apr;20(4):342-4
pubmed: 24710377
Breast Cancer. 2016 Jan;23(1):120-127
pubmed: 24906662
Ann Oncol. 2014 Sep;25(9):1729-35
pubmed: 25009010
Breast Cancer Res. 2014 Aug 09;16(4):421
pubmed: 25107527
Clin Chem. 2015 Jan;61(1):112-23
pubmed: 25388429
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Ann Oncol. 2015 Aug;26(8):1715-22
pubmed: 25851626
Clin Chem. 2015 Jun;61(6):838-49
pubmed: 25896989
EMBO Mol Med. 2015 Aug;7(8):1034-47
pubmed: 25987569
Nat Commun. 2015 Nov 04;6:8760
pubmed: 26530965
Nat Commun. 2016 Jun 22;7:12008
pubmed: 27328849
Clin Cancer Res. 2017 Jan 1;23(1):88-96
pubmed: 27334837
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Cancer Cell. 2017 Aug 14;32(2):169-184.e7
pubmed: 28810143
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Ann Oncol. 2018 Feb 1;29(2):490-496
pubmed: 29112704
J Clin Oncol. 2018 Feb 20;36(6):543-553
pubmed: 29298117
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1871-1876
pubmed: 29432176
Int J Cancer. 2018 Sep 1;143(5):1236-1248
pubmed: 29574703
Int J Cancer. 2019 Jun 15;144(12):3127-3137
pubmed: 30536653
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347